Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for assessment of hepatic function and portal blood flow

a technology of portal blood flow and hepatic function, which is applied in the field of portal blood flow assessment and hepatic function assessment, can solve the problems of invasive hepatic venous pressure gradient (hvpg), inability to monitor the hepatic function and portal blood flow of patients with liver disease, and lack of gold standard for psc disease severity assessment,

Inactive Publication Date: 2015-07-23
UNIV OF COLORADO THE REGENTS OF
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a way to estimate the flow of blood in the liver by giving a person a special drink containing a labeled substance. This method can be used to help diagnose and screen for hepatic disorders like CHC, NAFLD, and PSC. The drink is simple and only requires a single blood sample to be taken 60 minutes after taking the drink.

Problems solved by technology

There are difficulties in monitoring hepatic function and portal blood flow in patients with liver disease.
The assessment of disease severity in PSC lacks a gold standard, as liver biopsy has significant sampling error and is no longer recommended.
Hepatic Venous Pressure Gradient (HVPG) is invasive, expensive and impractical, and clinical models were really created to assess late-stage disease.
Difficulties in Monitoring Patients with Chronic Liver Disease.
The needle biopsy is a very small specimen of a very large organ and it is very difficult to obtain large enough pieces from enough locations for adequate sampling (Vuppalanchi et al., 2009, Clin Gastroenterol Hepatol.
However, the heterogeneity of lesions in NASH decreases the accuracy (Ratziu et al., 2005, Gastroenterology.
It is not practical to biopsy a third of the population especially since the method has an estimated error rate of 20% or greater.
Other standard liver blood tests are not very useful.
Deficiencies of Other Non-Invasive Test Methods.
BreathlD® has a methacetin metabolic test in FDA trials, but this method failed to detect early stage CHC in earlier studies (Braden et al., 2005.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for assessment of hepatic function and portal blood flow
  • Method for assessment of hepatic function and portal blood flow
  • Method for assessment of hepatic function and portal blood flow

Examples

Experimental program
Comparison scheme
Effect test

example 1

Estimating Portal Flow from a Single Blood Draw

[0145]The individual time point serum cholate concentrations from the FLOW and SHUNT tests in HALT-C and Early CHC studies were carefully analyzed and differences at 45, 60, and 90 minutes were found to be highly significant (p2=0.8) with the portal flow. An equation was derived that could transform the concentration (uM) at 60 min into an estimated portal flow (mL / min / kg) with 85% accuracy of the 5 point FLOW method. This led to the development of the STAT test, in which, in one embodiment, the patient drinks an oral dose of distinguishable cholate compound, e.g., deuterated-cholate, and gives a single blood sample after 1 hour. The accuracy of the STAT test relative to the FLOW test is shown in FIG. 8.

example 2

Efficacy of STAT (Estimated Portal Flow) in Detecting Hepatic Dysfunction

[0146]In the Early CHC study healthy controls had a portal flow of 34±14 ml / min / kg (mean±SD). Hepatic dysfunction was defined as a portal flow more than 1 SD below the control mean, a flow <20 ml / min / kg. In the early CHC group, about ½ the patients exhibited hepatic dysfunction. The estimated portal flows in the early CHC patients were calculated from the equation shown in FIG. 8 using their 60 min serum cholate level. The estimated flow could detect hepatic dysfunction with a sensitivity of 90%, a specificity of 85%, a positive predictive value (PPV) of 82%, and a negative predictive value (NPV) of 92%. These preliminary results demonstrate that a single blood sample after an oral cholate dose could be used to detect hepatic dysfunction in early stage CLD.

[0147]Furthermore, in the Early CHC study we analyzed the potential impact of STAT if used as a screening test. Currently adults are screened for liver disea...

example 4

Procedure for Performance of SHUNT and FLOW Assays with Analysis by HPLC-MS

[0165]Performance of FLOW (Oral Cholate Clearance Test) and SHUNT (Cholate Shunt Test) assays are disclosed in US 2010 / 0055734 and US 2008 / 0279766, each of which is incorporated herein by reference.

Collection and processing of samples.

Reagents and Supplies.

[0166]The following reagents and supplies are utilized in the Cholate Shunt and Cholate Clearance Test procedures. If the patient is undergoing only the oral cholate clearance test, the IV Solution and 25% Human Albumin for injection are omitted.

IV Solution—20 mg 24-13C-Cholic Acid in 5cc 1 mEq / ml Sodium Bicarbonate

PO test compounds 2,2,4,4-2H (40 mg) and Sodium Bicarbonate (600 mg)

25% Human Albumin for injection (5 ml) to be added to 24-13C-Cholic Acid solution.

IV supplies, including 250 mis NS, indwelling catheter, 3-way stopcock.

10 cc syringes for administering IV test compounds

7 cc red top tubes for sample collection

3 ml crovials for serum storage

Needle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 61 / 491,429, filed May 31, 2011, the entire contents of which are incorporated herein by reference.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under grant numbers Contract No. N01-DK-9-2327 and M01RR-00051 awarded by the National Institutes of Health. The government has certain rights in this invention.BACKGROUND OF THE INVENTION[0003]All liver diseases have common pathophysiologic characteristics with disease progression fueled by inflammation, accumulation of fibrosis, and alteration of the portal circulation. There are difficulties in monitoring hepatic function and portal blood flow in patients with liver disease. Such diseases include chronic hepatitis C, nonalcoholic fatty liver disease (NAFLD), primary sclerosing cholangitis (PSC), chronic hepatitis B, alcoholic liver disease, autoimmune liver disease, c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/49A61J1/05
CPCA61J1/05G01N33/49G01N33/92G01N2800/085Y02A90/10
Inventor EVERSON, GREGORY THOMASHELMKE, STEVE MARK
Owner UNIV OF COLORADO THE REGENTS OF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com